Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyAspirus Arise 340B TB modifier Policy Update | Ope…
    Ask Trek AI about this page
    CurrentAspirus ArisePolicy N/A

    340B TB modifier reporting and payment for Part B drugs

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aspirus Medicare Advantage billing and payment expectations for drugs and biologicals acquired through the 340B Drug Pricing Program, including required use of modifier TB and related payment methodology for hospital outpatient services.

    Policy Summary
    PayerAspirus Arise
    Policy340B TB modifier reporting and payment for Part B drugs
    Policy CodePolicy N/A
    Change TypeMaterial revisions and clarifications
    Effective DateMar 4, 2025
    Last ReviewMar 4, 2025
    Next Review DateMar 4, 2025
    Key ActionSubmit 340B claims with bill type 13x and append -TB to HCPCS lines for drugs acquired through the 340B Program.
    SourceLink
    POLICY UPDATE CHANGES

    As of January 1, 2025, CMS requires all 340B covered entities to exclusively report modifier 'TB' on claim lines for drugs acquired through the 340B Drug Discount Program.

    Effective for claims paid on or after September 28, 2022, Aspirus implemented payment updates to allow the full rate (generally ASP plus 6%) for 340B purchased drugs in accordance with CMS guidance.

    Jan 1, 2025date TB modifier mandatory
    Dec 31, 2024

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    date JG removed
    9/28/2022full rate effective
    13xrequired bill type
    -TBmodifier to append

    Coverage and Payment Criteria

    Aspirus 340B modifier and payment criteria

    Coverage and payment stance for 340B-acquired Part B drugs and biologics furnished by hospitals paid under OPPS:

    Claims for separately payable Part B drugs and biologicals acquired through the 340B Drug Pricing Program and furnished by providers paid under the Medicare Outpatient PPS (OPPS) must include the -TB modifier on HCPCS claim lines for Aspirus Medicare Advantage (per CMS requirement effective 1/1/2025).
    Submit 340B claims with bill type 13x; append -TB modifier to HCPCS lines; ensure the submitted HCPCS is identified as eligible for 340B purchase; and the provider's payment is based on hospital outpatient methodology.

    Payment methodology (date-dependent)

    • For claims paid on or after 9/28/2022: Aspirus implemented payment updates to revert to allowing the full rate (generally ASP plus 6%) for 340B purchased drugs, in accordance with CMS guidance.
    • For claims paid prior to 9/28/2022: Aspirus paid an adjusted amount equal to ASP minus 22.5% (a discount of 26.9% of the fee schedule rate) for certain separately payable 340B drugs/biologicals furnished by hospitals paid under OPPS.
    Historical reporting: Prior to 1/1/2025 CMS permitted reporting either modifier JG or TB; modifier JG was removed from eligible 340B modifiers effective 12/31/2024.

    Coding and Payment Dates

    340B modifiersModifierCovered
    TBDrug or biological acquired with 340B Drug Pricing Program discount (informational)
    JGFormerly permitted 340B modifier; removed 12/31/2024
    Payment methodology date breakpoint
    Effective dateClaims paid on or after September 28, 2022 revert to full rate (generally ASP+6%).
    Prior payment methodologyClaims paid prior to September 28, 2022 were paid under an adjusted ASP minus 22.5% methodology (equating to a 26.9% discount of the fee schedule for certain drugs).
    Reason for changeReversion to full rate implemented in accordance with CMS guidance following court ruling and related CMS payment updates.

    Provider Billing & Submission Requirements

    Billing Rule

    340B claim submission: bill type 13x and mandatory -TB modifier

    Submit outpatient Part B drug claims acquired through the 340B Program using bill type 13x and append the -TB modifier to each HCPCS line for drugs acquired through 340B; ensure the HCPCS is identified as eligible for 340B purchase and that payment is under hospital outpatient methodology. Note that CMS requires exclusive use of modifier TB on claim lines for separately payable Part B drugs acquired through 340B effective January 1, 2025 (JG was removed 12/31/2024).

    • Use bill type 13x for 340B claims.
    • Append modifier -TB to HCPCS lines for drugs acquired through the 340B Program.
    • Identify the submitted HCPCS as eligible for 340B purchase.
    • Ensure provider payment is based on hospital outpatient (OPPS) methodology.
    • As of 1/1/2025, report TB exclusively; JG was removed from eligible modifiers 12/31/2024.

    Key Definitions

    TB modifier (340B informational)
    Modifier TB definitionDrug or biological acquired with 340B Drug Pricing Program discount, reported for informational purposes for select entities.
    Mandatory reportingAs of January 1, 2025, CMS requires all 340B covered entities to exclusively report modifier 'TB' on claim lines for drugs acquired through the 340B Drug Discount Program.
    Prior practicePrior to January 1, 2025, CMS permitted reporting either modifier 'JG' or 'TB'.
    Required bill type for 340B claims
    Required bill typeBill Type 13x is required for submitting 340B claims under Aspirus Medicare Advantage.
    Associated requirementsTB modifier must be appended to HCPCS lines and the submitted HCPCS identified as eligible for 340B purchase.
    Policy Summary
    PayerAspirus Arise
    Policy340B TB modifier reporting and payment for Part B drugs
    Policy CodePolicy N/A
    Change TypeMaterial revisions and clarifications
    Effective DateMar 4, 2025
    Last ReviewMar 4, 2025
    Next Review DateMar 4, 2025
    Key ActionSubmit 340B claims with bill type 13x and append -TB to HCPCS lines for drugs acquired through the 340B Program.
    SourceLink
    On This Page
    Coverage and Payment CriteriaCoding and Payment DatesProvider Billing & Submission RequirementsKey Definitions
    Payment basisProvider payment is based on hospital outpatient methodology for 340B claims submitted with Bill Type 13x.